Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study
- Resource Type
- Article
- Authors
- Roussel, Murielle ; Lauwers-Cances, Valérie; Macro, Margaret; Leleu, Xavier; Royer, Bruno; Hulin, Cyrille; Karlin, Lionel; Perrot, Aurore; Touzeau, Cyrille; Chrétien, Marie-Lorraine; Rigaudeau, Sophie; Dib, Mamoun; Nicolas-Virelizier, Emmanuelle; Escoffre-Barbe, Martine; Belhadj, Karim; Mariette, Clara; Stoppa, Anne-Marie; Araujo, Carla; Doyen, Chantal; Fontan, Jean; Kolb, Brigitte; Garderet, Laurent; Brechignac, Sabine; Malfuson, Jean-Valère; Jaccard, Arnaud; Lenain, Pascal; Borel, Cécile; Hebraud, Benjamin; Benbrahim, Omar; Dorvaux, Véronique; Manier, Salomon; Augeul-Meunier, Karine; Vekemans, Marie-Christiane; Randriamalala, Edouard; Chaoui, Driss; Caers, Jo; Chaleteix, Carine; Benboubker, Lofti; Vincent, Laure; Glaisner, Sylvie; Zunic, Patricia; Slama, Borhane; Eveillard, Jean-Richard; Humbrecht-Kraut, Catherine; Morel, Véronique; Mineur, Philippe; Eisenmann, Jean-Claude; Demarquette, Hélène; Richez, Valentine; Vignon, Marguerite; Caillot, Denis; Facon, Thierry; Moreau, Philippe; Colin, Anne-Laurène; Olivier, Pascale; Wuilleme, Soraya; Avet-Loiseau, Hervé; Corre, Jill; Attal, Michel
- Source
- In Blood 5 May 2022 139(18):2747-2757
- Subject
- Language
- ISSN
- 0006-4971